Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.04B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 22.16%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 22.16%.
Fairly Valued
The company’s latest PB is 4.22, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 28.38M shares, decreasing 6.62% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.65.